EyePoint Pharmaceuticals Launches $150M Public Offering to Fund Drug Pipeline

EyePoint Pharmaceuticals is raising $150M to push its drug pipeline forward. The company's stock price has dipped following the announcement.

, and Administrator

2025 October 15 . 2:00 AM

1 min read

This image is clicked in a room, where it looks like Store. There are so many bottles in this image... — This image is clicked in a room, where it looks like Store. There are so many bottles in this image and cans. There is a Banner in the middle which is indicating Supra brand. Bottom right corner there is a logo LM.

EyePoint Pharmaceuticals Launches $150M Public Offering to Fund Drug Pipeline

EyePoint Pharmaceuticals (NASDAQ: EYPT) has initiated an underwritten public offering, aiming to raise $150 million by selling shares of its common stock. The company's stock price has dipped to $12.45 after hours, a decrease of 5.39%.

The offering includes an option for underwriters to purchase up to an additional $22.5 million of shares within 30 days. JP Morgan has also secured the right to acquire up to $22.5 million more shares during this period. EyePoint plans to utilise the net proceeds to accelerate the clinical development of DURAVYU for wet AMD and DME, bolster its early-stage pipeline, and cover general corporate expenses.

EyePoint Pharmaceuticals' public offering aims to secure $150 million, with the potential to increase to $172.5 million. The company intends to allocate these funds strategically to advance its drug pipeline and support its operations.